ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

PTC will acquire controversial DMD drug

by Michael McCoy
March 20, 2017 | APPEARED IN VOLUME 95, ISSUE 12

PTC Therapeutics has agreed to acquire the Duchenne muscular dystrophy (DMD) treatment Emflaza from Marathon Pharmaceuticals for $140 million plus potential milestone payments. Marathon won FDA approval for Emflaza on Feb. 9 and immediately stirred controversy by pricing it at $89,000 per year, even though it is based on the generic steroid deflazacort. The firm subsequently paused the launch. PTC, which already markets the DMD treatment ataluren in Europe, says it is finalizing commercialization plans.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment